Tuesday, 16 June 2020

Dental Consumables Market Overview With Detailed Analysis, Competitive Landscape, Forecast To 2024

Market Scenario:
Acknowledging the developments and accruals the market is enjoying currently, Market Research Future (MRFR) in its recently published study report asserts that the global dental consumables market will be valued at USD 28,345 MN by 2024, registering approximately 7 % CAGR during the forecast period (2016 – 2024). 
The global market of dental consumables, including US dental consumables market is growing pervasively mainly due to the technological advancements that took place in the dental industry. Although the integration of technology & consumables in dental practices goes back to decades, the uptake of consumables has been increasing over the past few years, and so is increasing the growth of the dental consumables market. Furthermore, factors such as the wide adoption of dental consumables along with the increasing geriatric populace, prevailing dental disorders and surgeries are driving the market growth.
The growing spread of the dentistry field has been a massive driver for the global dental consumables market over the forecast period. The field of dentistry has evolved rapidly in modern times to encompass several specialties such as orthodontics, prosthodontics, and endodontics. This has led to a growing demand for a number of procedures in the dentistry field as well as for the consumables used in these procedures. The rapid evolution of the dentistry field is likely to remain a major driver for the global dental consumables market over the forecast period. The growing insistence on single-use consumables, in order to ensure the sterility and safety of the component in each procedure, is also likely to drive the demand from the dental consumables market over the forecast period. While the field of dentistry has grown to encompass several sub-specialties, the instruments and equipment used by the various fields are largely similar, leading to a steady growth in demand from the dental consumables market.
The growing demand for dental procedures due to the growing prevalence of conditions such as plaque and dental caries is likely to remain a major driver for the global dental consumables market over the forecast period. Growing consumption of chocolate and candy among the younger generation has led to a growing prevalence of dental problems around the world, leading to a growing demand for dental procedures and thus for dental consumables. The growing disposable income of consumers in emerging regions is also likely to be a key driver for the global dental consumables market over the forecast period.
On the other hand, these dental consumables are costlier especially in developing and underdeveloped nations which in turn, is hampering the market growth in these regions restricting the uptake of consumables. Also, the operational complexities of these consumables may restrain the growth of this market.
Competitive Analysis:
Leading players in the global Dental Consumables Market Companies include Septodont, Straumann, KERR Corporation, EnvisionTEC, American Orthodontics, Dentsply Sirona, Nobel Biocare, Planmeca OY, Patterson Dental, GC Orthodontics, Henry Schein, and 3M.
In March 2019, the NHS announced a planned price increase for dental procedures from April 1. The price increase covers minor dental procedures as well as major operations such as root canal. This could have a key impact on the dental consumables market in Europe over the forecast period.
Segmentation:
The global dental consumables market is segmented on the basis of type and region.
By type, the global dental consumables market is segmented into dental implants, dental restorative materials, dental prosthetics, dental regenerative materials, and others. The dental implants segment is likely to remain the top earner in the global dental consumables market over the forecast period due to the growing demand for dental implants for health as well as cosmetic reasons.
Regional Analysis:
The global dental consumables market is segmented by region into Americas, Europe, Asia Pacific, and the Middle East and Africa.
Europe holds the largest share in the global dental consumables market by region and is likely to remain the leading revenue generator in the market over the forecast period due to the growing demand for advanced dental procedures in the region and the widespread availability of dental healthcare facilities. The growing scope of the healthcare sector in the region is likely to enable smooth growth of the dental consumables market over the forecast period.
Asia Pacific is likely to exhibit the fastest growth in the global dental consumables market over the forecast period due to the growing disposable income of consumers in the region and the growing prevalence of dental conditions requiring complicated operations and surgical procedures.
The Americas is also likely to hold on to a major share in the global dental consumables market due to the strong presence of several leading players in the dental consumables industry and the high spending power of the geriatric demographic in the region, which plays a key role in the growth of dental services and equipment.
Posted by at No comments:

CBD Market Covering Growth Inclinations & Development Strategies until 2027

CBD Market Overview
The Global Cannabidiol Market is expected to register a CAGR of 125.58% to reach USD 22,07,162.54 Million by 2026.
Cannabidiol (CBD) is a safe, non-addictive substance found in the cannabis plant. CBD is the second-most abundant cannabinoid found in cannabis after tetrahydrocannabinol (THC). CBD has significant therapeutic benefits such as anti-inflammatory, analgesic, anti-anxiety, and seizure-suppressant properties. According to a survey by the National Center for Biotechnology Information (NCBI) conducted between 2017 and 2018, about 62% of the population used CBD to treat a medical condition.
The growing research & development and financial support by various private and government organizations for cannabinoid research, rising occurrence of chronic diseases and related complications, and legalization of CBD in various regions are expected to have a positive impact on the global cannabidiol (CBD) market. However, adverse effects associated with cannabis and stringent government policies are anticipated to restrain the growth of the global CBD market.
CBD Market Dynamics
Growing research and development activities and financial support by various private and government organizations for cannabinoid research- There are many private and government organizations supporting the research and development for cannabinoids for medical purposes. Cannabis has numerous medicinal properties by which it can cure various diseases. According to the National Institute of Drug Abuse, May 2018 publication, in 2017, the National Institute of Health (NIH) supported 330 projects and spent USD 140 million on cannabinoid research and development. During this investment, USD 36 million was spent on 70 projects to examine the therapeutic properties of cannabis, and USD 15 million was spent on 26 projects centered on cannabinoid (CBD). Even in 2016, NIH spent USD 21 million studying therapeutic properties of cannabinoids. Singapore, known for the world's most stringent drug laws, is also funding research projects on medical treatments containing synthetically derived compounds of the cannabis plant. In 2017, the government-run National Research Foundation launched a program to research the therapeutic potential of cannabinoids.
CBD Market Regional Analysis
The Americas dominate the global CBD market, owing to the increasing consumption of cannabis-based products. According to the World Health Organization (WHO), the consumption of marijuana has an annual prevalence rate of nearly 2.5% of the global population, i.e., approximately 147 million individuals. It is also reported that approximately 22.2 million Americans of 12 years of age and older use cannabis and related products for various reasons.
Europe holds the second largest market share due to the rising awareness about clinical applications of cannabis. CBD is legal and can be openly marketed in certain European countries, for instance, the Ministry of Agriculture, Food and Forestry, and the Bulgarian Food Safety Agency issued the ‘free certificate of sale’ for the CBD products. Thus, such approvals and consideration by the regulatory agencies in Europe are driving the CBD market growth in the region. In spite of the approvals and considerations, there are positive restrictions associated with the use of the products. For instance, in 2013, medical cannabis was legalized in the Czech Republic, but it was limited to 180 grams of dry matter per month. In Europe, marijuana and cannabis laws differ from country to country. Previously, Germany was importing medical cannabis from other countries, but in 2017, Germany passed a law to expand access to medical cannabis and to allow domestic production. Increasing participation of various companies such as Medical Marijuana Inc., as a scope of development, announced the formation of Canipa Holdings in Romania, European Union. The effect of such initiatives by the companies is facilitating the growth of the CBD market in the European region.
The Asia-Pacific region is classified into CBD Market China, CBD Market India, CBD Market Japan, and Rest of Asia-Pacific. It holds the third largest position in the CBD market. Recently, China has legalized the cultivation of CBD (Hemp) and extraction for the derived product. The products are exported and not sold in China. Yunnan provincial government and Public Security Bureau approved the first industrial hemp plant extraction factory in China. It is the largest country in terms of area, population, businesses, and others. The entry of Chinese companies in the CBD market has created a great potential for expansion and growth. In Asia-Pacific, cannabis-based products are completely unacceptable. But due to the increasing cases of epilepsy, cannabis-based products are prescribed by some physicians. For instance, a recent Australian nationwide survey of 976 people with epilepsy indicated that 13% of the parents were using illicit cannabis extracts to manage their child’s seizures. Australia mainly focuses on the medical use of cannabis products. Australian regulatory agencies are operating on providing a guideline for the use of the CBD products. This is expected to help in the growth of the CBD market in Australia.
The Middle East and Africa is expected to witness a restricted growth due to stringent government policies, adverse effects associated with cannabis, and the illegal use of marijuana. In the Middle East, few of the Arab countries are imposing trick laws over the use and handling of cannabis-related products. Thus, the CBD market in these regions has limited scope for growth during the forecast period.
Segmentation
On the basis of form, the global cannabidiol market is segmented into solid and liquid.
In the solid form of CBD, the report covers CBD crystals, CBD wax, capsule/softgel, hash, and others. The liquid form of CBD includes CBD oil, tincture, cream, e-liquid, and others.
CBD crystals are a pure form of CBD isolates. CBD crystals are produced by heating CBD rich extract and then continuous cooling and separating it. CBD crystals are generally used to manufacture CBD infused edibles and creams. CBD wax is solidified or crystalized full spectrum form of CBD. CBD wax is a highly concentrated form of CBD and especially used for pain relief. CBD capsules are similar in comparison to capsules as they are surrounded by an outer shell, usually gelatin. CBD soft gelatin capsule is a translucent golden shade standard capsule that is filled with hemp oil and sometimes olive oil as filler.
CBD oil is one of the most popular and widely available forms of CBD. It is specifically used for medical purposes as it provides fast and effective results. There are a wide variety of flavors of full spectrum CBD oils available in the market. CBD tinctures are made from high strains of hemp, with 60-70% of alcohol. CBD tinctures are primarily used to relieve anxiety and ease the pain. CBD infused e-liquid are used as a fluid in electronic cigarettes and vaporizers.
CBD Market Key Players
The prominent players in the global CBD market are Aphria Inc., Folium Biosciences, Freedom Leaf, Inc, Green Roads of Florida, LLC, CBD Health Solutions, LLC, ENDOCA, Isodiol International Inc, CV Sciences, Inc, Medical Marijuana, Inc., Canopy Growth Corporation, Elixinol Global Limited.
The players operating in the global CBD market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cbd-market-8090 
Posted by at No comments:

Healthcare Revenue Cycle Management Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2027

Healthcare Revenue Cycle Management Market Size analysis, by Product Type (Integrated, Standalone Software) Component (Software, Services) Deployment (On Premise, Cloud Based) End-user (Hospital, Ambulatory Service)- Global Forecast Till 2027
Market Scenario
Market Research Future Published a Cooked Research Report on Healthcare Revenue Cycle Management Market Analysis Report – Forecast to 2027.
Healthcare revenue cycle management (RCM) is a software that manages and simplifies all administrative and clinical functions including claims process, payment, revenue generation, patient registration, medical documentation, insurance verification, and accounts receivable & collections. Healthcare revenue cycle management software has gained profound importance in the healthcare sector in recent years. The global healthcare revenue cycle management market is anticipated to register a CAGR of 12.2% over the forecast period of 2017-2027, asserts Market Research Future (MRFR) in a detailed research report.
Towering costs of surgeries and overall healthcare has prompted hospitals to resort to technologies to reduce burden. Simplification of financial transactions is a key growth motivator which has spurred the adoption of RCM software among hospitals. In addition, expansion of healthcare budget and increase in a number of hospital chains and healthcare services across the globe fares well for the market. RCM software allows healthcare institutions to not only increase accuracy and timeliness but also helps them adhere to continuously evolving regulatory norms. RCM software can be applied to every aspect of the revenue cycle and is gaining traction among healthcare institutions.
On the downside, the growth of the global healthcare revenue cycle management market might be deterred by a dearth of trained healthcare professionals to operate the software. The global healthcare revenue cycle management market is anticipated to reach USD 1,75,163.5 Mn by the end of 2027.
Key Players for Global Healthcare Revenue Cycle Management (RCM) Market
  • Epic Systems Corporation (US),
  • McKesson Corporation (US),
  • Cerner Corporation (US),
  • General Electric Company (US),
  • Allscripts (US),
  • Quest Diagnostic (US),
  • Siemens Healthcare (Germany),
  • AdvantEdge Healthcare Solutions (US),
  • CareCloud (US),
  • Acelerartech (US),
  • 3M (US).
Intended Audience
  • Healthcare Revenue Cycle Management (RCM) Products Manufacturers
  • Healthcare Revenue Cycle Management (RCM) Products Providers
  • Medical Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors

Segmentation                                                                                                                                 
The global healthcare RCM market is segmented on the basis of deployment, component, product types, and end users.
On the basis of deployment, the market is segmented into on-premises, and cloud-based.
On the basis of component, the market is categorized into services, and software.
On the basis of product types, the market is divided into integrated software, and standalone software.
On the basis of end users, the market is shared into hospitals, ambulatory services and others.
Posted by at No comments:

Neurostimulation Devices Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2022

Market Scenario:
Neurostimulation is a modulation of the nervous system’s activity. It is deliberately carried out by using invasive and non-invasive techniques. Implantable stimulation devices are most commonly used in the treatment of the neurological conditions such as epilepsy, Parkinson’s disease, dystonia, tremors, depression, obsessive compulsive disorder, diabetic neuropathy and few other conditions. Increasing cases of the neurological disorders such as chronic pain and depression high adoption of the Neurostimulation therapy are likely to improve the market of Neurostimulation devices. Globally, this Neurostimulation Devices Market Size is growing steadily and it is anticipated to show an exponential growth reaching approximately $11.5 billion in 2022
Segments:
Global Neurostimulation devices market has been segmented on the basis of type which comprises implantable devices, and external devices. Implantable devices include deep brain stimulators, spinal cord stimulators, sacral nerve stimulators, gastric electric stimulators, cochlear implants, and vagus nerve stimulators; whereas external devices include transcutaneous electrical nerve stimulator, and transcranial magnetic stimulator. On the basis of application, the market is segmented into dystonia, epilepsy, Parkinson's disease, depression, gastroparesis, pain management, tremors, urinary and fecal incontinence, and others. On the basis of end user, market is segmented into hospitals/clinics, cognitive care centers, research institutes and others.
Regional Analysis of Neurostimulation devices Market:
Considering the global scenario of the market, Americas region is believed to be the largest market for Neurostimulation devices. Moreover, the European market is also growing continuously and slowly catching up with the American market. On the other hand, Asia-Pacific market is expected to grow at the fastest pace in the Neurostimulation devices segment during the forecast period. Middle East & Africa region are likely to have a limited but steady growth in the market.
Key Players for Neurostimulation devices Market:                                     
Some of the key players in this market are: Autonomic Technologies, Boston Scientific, ElectroCore, ImThera Medical, Inspire Medical Systems, LivaNova (Cyberonics), Medtronic, NeuroMetrix, NeuroPace, Neuros Medical, NeuroSigma, Nevro Corporation, SPR Therapeutics, St.Jude Medical, Synapse Biomedical, and others.   
Regional Market Summary 
Geographically, the Americas is anticipated to dominate the global Neurostimulation Devices market owing to the rising prevalence of the cardiovascular diseases such as cardiac arrhythmia, arterial blockage, and coronary artery disease among others. The development of the better therapeutic approaches and advanced treatment procedures have affected the growth of the American market in a positive way.
According to the data published by the Department of Health, New York in May 2018, percutaneous coronary intervention is one of the two most common procedures performed on patients with coronary artery disease. Besides this, the high medical awareness among American population, high disposable income, presence of the top medical device manufacturers in the region are some of the many factors that drive the growth of the Neurostimulation Devices market in this region.
Europe is expected to hold the second largest market share in the global Neurostimulation Devices market. The market growth in this region is majorly attributed to the increasing government support for the device manufacturers. Geographical expansion of companies has led to the wider reach of the medical products and services which has brought a huge change in terms of the acceptance and implementation of the new products as well as procedures. Similarly, Asia-Pacific region has observed a rapid growth in the Neurostimulation Devices market owing to the development in the medical sector in developing countries like India and China. Moreover, increase in government funding for healthcare, rising R&D expenditure, and growing number of medical device companies in the region has led to its fastest growth during the forecast period. The Middle East and Africa region is anticipated to show minor growth opportunities in the Neurostimulation Devices market during the forecast period.
Posted by at No comments:

2020 Worldwide Meningococcal Vaccines Market Analysis, Market Share, Application Analysis, Regional Outlook, Competitive Strategies & Forecast by 2025

Market Forecast
Meningococcal Vaccines Market has a demand for USD 172 Million doses in 2019. Further, the global estimated supply in 2019 is expected to be 203 Million doses.
Market Synopsis
Meningococcal meningitis is a bacterial infection caused by Neisseria meningitides. Disease incidence is high in West and Central Africa, where historically, serogroup A has been the most important cause of disease. More recently, meningitis outbreaks have gradually been associated with serogroup C, and to a lesser extent, serogroup W.
The meningococcal vaccines market is complex and diverse, with regional variations in serogroup distribution with substantial use outside routine immunization. The vaccine has approximately 29 marketed products targeting various combinations of the six serogroups (A, B, C, W, X, Y).
Market Influencer
Without an increase in production, the existing supply of conjugate MenACWY will be inadequate to meet the demand generated by the rising incidence of serogroups C and W, and the low availability of polysaccharide vaccines. Further, several multivalent, conjugate vaccines by Chinese and Indian manufacturers are in the pipeline, and, if prequalified they will be registered for use in many geographies. Moreover, if they are made available at acceptable prices it could increase global demand in Meningococcal Vaccines Market.
Market Drivers
  • Rise in prevalence of the meningococcal disease
    • According to a document published by the U.S. Department of Health & Human Services, in 2017, there were approximately 350 cases of meningococcal disease reported. The disease has an incidence rate of 0.11 cases per 100,000 people in the United States. Any population group can be affected by the disease, with maximum prevalence in children younger than one-year-old and a second peak in adolescence. Adolescents and young adults, ranging from 16 to 23 years old, have the highest rates of meningococcal disease.
    • Further, increasing incidence of meningococcal disease in West and Central Africa regions is expected to drive the demand in the African region
  • Booming mortality of the meningococcal disease is leading to increasing demand for the vaccines
    • Approximately 10 to 15 in 100 people affected with meningococcal disease will face mortality. Further, up to 1 in 5 survivors will have long-term disabilities, such as loss of limb, deafness, and damage to the nervous system brain among others
  • Escalating positive results with the vaccines to boost the demand in the market
  • Growing research and development activities by prominent players in the industry
Market Restraints
  • Withdrawn production of polysaccharide vaccines has resulted in reduced country access, particularly for MICs in various regions. For example, Sanofi Pasteur, manufacturer of Menomune, declared in 2017 that the company is discontinuing the production of the vaccine. With the production of Menomune at hold, there were no polysaccharide vaccines approved for use in the United States

Meningococcal Vaccines Market Segmentation

By treatment, the market is segmented into Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine.
Meningococcal A conjugate vaccine is significantly used in mass campaigns across affected regions like Africa. Since 2010, the vaccine has significantly decreased meningococcal disease incidence in the region. However, the demand for meningococcal A conjugate in the country remains uncertain given that national immunization program adoptions are based on the timing of Gavi funding decisions, the country’s readiness, and competing for vaccine introduction priorities.
In the polysaccharide segment, products such as MenACWY vaccines are in high demand. MenACWY vaccine is the most desirable combination, given its broader serotype coverage. MenACWY specifically has nine products that are available across polysaccharide and conjugate product segments, but conjugate products are suggested for use in routine immunization activities.
Moreover, the demand and supply of Subcap MenB vaccines is restricted to HICs and influenced by their acceptance into NIPs. Improved uptake of MenB vaccines is expected in the coming years but will likely be moderate and limited to high-income markets given the high price and competing interest of introducing MenACWY conjugate.
By end-user, the market is segmented into Hospital & Clinical, Research Laboratories, and Academic Institutes
Hospitals and clinics control the global market for meningococcal vaccines. The high growth of hospitals and clinics segment is attributed to the increasing application of vaccines in these healthcare facilities in conjunction with the growing prevalence and incidence of the meningococcal disease.
Moreover, research laboratories and academic institutes take up the second-largest share due to the boost in research and development in the market.
By region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
In the global market, China is expected to have the largest market share, which accounts for approximately 35% of the global demand. This is primarily due to polysaccharide products, which currently comprise 84% of China’s demand. Chinese suppliers presently focus only on meeting the demand of the domestic market, but some of the manufacturers have indicated interest in the global market as well. The dynamic product pipeline with several multivalent conjugate products in development may trigger changes in the future supply mix of the Chinese market. Moreover, in China, non-routine use (excluding campaigns) accounts for an estimated 9 million doses in 2019, which may help to sustain the huge market share in the forecast period.
UNICEF foresees all 26 African countries in the meningitis belt, which have completed mass campaigns in 2016. In 2015, seven countries in the region were introduced with meningococcal A conjugate vaccine through their mass campaigns and targeted a population of 233 million. Further, during 2016-2018, UNICEF introduced meningococcal A conjugate vaccine in 26 countries. Ghana was the first country to be introduced with the vaccine into its RI schedule in 2016. Also, four other countries including Mali, Niger, Nigeria, and Sudan introduced the vaccine into RI programs in 2016.
Key Developments in the Global Meningococcal Vaccines Market
  • In 2018, Pfizer granted FDA Breakthrough Therapy designation for Trumenba (Meningococcal Group B Vaccine). This vaccine plays a major role in the prevention of invasive meningococcal B disease in children aged 1 to 9 years
  • In 2018, GSK’s meningitis B vaccine Bexsero received Breakthrough Therapy designation from the US FDA for prevention of Invasive Meningococcal Disease for children 2-10 years of age
  • In 2015, Novartis Bexsero vaccine was approved by the FDA for the prevention of meningitis B. This vaccine is used as active immunization to prevent invasive meningococcal disease caused by serogroup B
Key Players
  • Baxter international
  • Pfizer Inc.
  • Sanofi S.A.
  • Novartis Pharmaceuticals Inc.
  • JN-International Medical Corporation
  • Serum Institute of India Ltd.
  • GlaxoSmithKline
  • BIO-MED
  • Others
Posted by at No comments:

Thalassemia Treatment Market Growth Analysis, Industry Trends, and Forecast by 2025

Market Forecast
Thalassemia Treatment Market Size is expected to cross USD 3763 Million by 2025 at a CAGR of 10.4%.
Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.
Market Synopsis
Thalassemia Treatment Market analysis asserts that, Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.
Market Influencers
Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the market.
Market Drivers
  • The rising incidence of thalassemia is expected to drive the growth of the market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world.
  • Increasing pipeline drugs in thalassemia is expected to drive the growth of the market. There are approximately 15 pipeline products under clinical trials for the treatment of thalassemia. For instance, in December 2016, Kiadis Pharma announced initiation of Phase I/II clinical trial with ATIR201 for thalassemia.
  • A rise in awareness regarding available treatment options for the treatment of thalassemia is expected to drive the growth of the market.
  • The rise in demand for improved curative gene therapy is expected to drive the growth of the market.
Market Restraints
  • Stringent regulatory policies
  • High treatment costs
Segmentation
By Type
  • Alpha-thalassemia: Fastest growing segment. It is one of the most common autosomal recessive disorders. There is an increased incidence of the alpha-globin disorders in the US and other Western nations which eventually drives the growth of the thalassemia treatment market. However, about 5% of the world’s population is affected by alpha-thalassemia.
  • Beta Thalassemia: It is caused by reduced or no production of beta-globin subunits. About 1.5% of the global population is affected by Beta-thalassemia.
By Treatment
  • Blood Transfusions: The largest growing segment owing to the low risks involved due to careful blood screening. This treatment gives strong red blood cells along with normal hemoglobin. About 56,000 population have major thalassemia, wherein, at least 30,000 need regular blood transfusions. Thus, rising demand for blood transfusions is expected to drive the growth of the market.
  • Iron Chelation Therapy: This includes removing excess iron from the bloodstream. Iron chelator drugs such as desferrioxamine, deferiprone, and deferasirox are majorly used in this treatment.
  • Folic Acid Supplements: Folic acid is vitamin B that helps build strong red blood cells. These supplements are majorly consumed during and after pregnancy. However, 4% had started consuming after becoming pregnant. Thus, the increased use of folic acid is expected to drive the growth of this segment.
  • Gene therapy: Scientists are investigating genetic techniques to treat thalassemia. Gene therapy named Zynteglo was first launched by Bluebird Bio, Inc. (US) in September 2019.
  • Bone Marrow transplants: These transplants are not done very often as significant risks are involved but can be tried if no bone marrow matched donor is available. However, the patient will not need further blood transfusions if this transplantation is done. As a result, it would drive the market growth in this segment.
By End-User
  • Hospitals & Clinics: Holds the largest market share owing to the increase in the number of hospital admissions for the treatment of thalassemia. Moreover, increasing occurrence of thalassemia is also expected to drive this segment.
  • Diagnostic laboratories: This segment holds significant market share owing to the increasing awareness regarding thalassemia treatment.
  • Others: This segment includes research laboratories, educational institutes, among others.
By Region
  • Americas: The largest growing regional market owing to rising awareness about thalassemia and increasing government efforts to support gene therapy. However, Beta-thalassemia disorder is relatively rare in the US.
  • Europe: The introduction of gene therapy for the treatment of thalassemia is expected to boost the growth of market. For instance, in September 2019, Bluebird Bio, Inc. (US) has obtained approval for gene therapy that would remove the need for blood transfusions for people with blood disorder beta-thalassemia.
  • Asia-Pacific: The fastest-growing regional market in thalassemia treatment. Increasing investment in healthcare infrastructure is expected to drive the growth of the market in this region.
  • Middle East & Africa: Increasing adoption rate of blood transfusion treatment in countries such as Turkey and GCC would drive the demand for thalassemia treatment in this region.
Key Players
  • Novartis AG (Switzerland)
  • Bluebird Bio, Inc. (US)
  • Kiadis Pharma (Netherlands)
  • CELGENE CORPORATION (US)
  • Sangamo Therapeutics (US)
  • Acceleron Pharma, Inc. (US)
  • Gamida Cell (Israel)
Posted by at No comments:

STD Testing Devices Market 2020 Growing Trend and Demand in Healthcare Sector 2025

Global STD Testing Devices Market Research Report, by Type (Laboratory Devices, Point of Care (PoC) Devices), End User (Hospitals and Clinics, Diagnostics Laboratories, Research and Academic Centers, Others), Region (Americas, Europe, Asia Pacific, Middle East and Africa) - Forecast till 2025
Market Forecast
STD Testing Devices Industry Market Growth Share accounted for USD 70.29 Billion in 2018 and is expected to register a CAGR of 9.3% during the forecast period.
Market Synopsis
Sexually transmitted disease (STDs) is an infection caused due to some organisms. STDs can be transmitted from one person to another through sexual activity and intimate contact. The cases of sexually transmitted diseases keep climbing among 45 and older Americans. 82,938 cases of gonorrhea, syphilis, and chlamydia were reported among 45 and older Americans in the year 2016.
Market Influencer
The increasing prevalence of lifestyle diseases, rising geriatric population along with increasing awareness about sex-related diseases is influencing the market growth positively. The increasing number of product launches by key players in the market are likely to act as a promising factor for the increase in the near future.  For Instance, Quest Diagnostics launched three new sexually transmitted disease (STD) laboratory test packages that individuals can purchase online for some of the most prevalent STDs in the United States.
Market Drivers
  • Increase in prevalence of sex-related diseases
    • Every year, 376 million new cases of chlamydia, syphilis, gonorrhea, and trichomoniasis are reported globally. The total estimated direct cost of STIs annually in the U.S. is about USD 16 billion.
    • The most common STIs affecting a lot of people are Chlamydia, gonorrhea, and syphilis. Approximately 1.5 million cases of chlamydia were reported in 2015 in US alone which represents it to be the highest number of annual cases of any condition ever reported.
    • A total of 89,239 cases of gonorrhea were reported by 27 states of the European Union in 2017.
  • Increasing prevalence of lifestyle diseases
  • Rise in healthcare expenditure
  • Increasing geriatric population
  • Increasing mergers & acquisitions by prominent players in the market
    • For instance, in 2019, the US Food and Drug Administration (FDA) has cleared two tests "The Aptima Combo 2 Assay (Hologic Inc) and the Xpert CT/NG (Cepheid)" to detect Chlamydia trachomatis and Neisseria gonorrhoeae from throat and rectum samples.
  • Increasing awareness about STIs
Market Restraints
  • Lack of information about the symptoms and causes is hampering the growth of the market.
Segmentation
By Type
  • Laboratory Devices: It is expected to hold a larger share. Laboratory devices are the traditional methods of detecting STI and a large number of hospitals and clinics are expected to be using the laboratory devices.
  • Point of Care (POC) Devices: It is expected to be the fastest-growing segment as it is less time-consuming.
By End-User
  • Hospitals and Clinics: Hospitals and clinics segment dominates the global market for The positive growth of hospitals is attributed to factors such as high volume of STD tests performed in hospital-based laboratories across the globe and growing patient population.
  • Diagnostic Laboratories: Diagnostic Laboratories segment take up the second-largest share due to the rising number of diagnostic labs and the increasing patient population.
  • Research Laboratories and Institutes: segment is projected to be the fastest-growing segment over the assessment period. The research and development activities with respect to STD diagnostics and treatment have increased in last decade which has resulted in the growing demand for the devices and kits in the R&D facilities. Besides that, government funding for the research and development for effective treatment of STD has pushed the growth of this segment. The researchers from King's College London, have published a study in Nature Communications, according to them skin vaccination can generate protective CD8 T-cells that are recruited to the genital tissues and could be used as a vaccination strategy for sexually transmitted infections (STIs).
By Region
  • Americas: It is the largest regional market owing to the factors such as large patient population, rise in prevalence of STIs, the availability of a wide variety of STD testing kits and surges in awareness about the causes of STIs and its treatments which are driving the growth of the market in this region.
    • According to the Centers for Disease Control and Prevention (CDC), more than 1300 cases of congenital syphilis, about 40% increase was reported in newborns during 2017-2018 in US. Similarly, a rise in 8487 new cases of women suffering from gonorrhea in US alone was reported during the year 2017-2018.
  • Europe: The key factors driving the market growth are the growing research and development support by government bodies for the healthcare sector, and the significant demand for STI testing is driving the growth of the STI testing devices market in Europe. Additionally, the rising initiatives by organizations are driving market growth. For Instance, EuroTEST initiative is a platform for information exchange and activities to improve early diagnosis and care of HIV, viral hepatitis, sexually transmitted infections, and tuberculosis.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global STI testing devices market. The rising patient population is driving the growth of the Asia-Pacific STI testing devices market. Additionally, increasing disposable income of the middle-class population, and improving healthcare infrastructure in emerging countries such as China and India are driving the market growth. However, unfavorable healthcare reforms may restrain the growth of the market to some extent.
  • Middle East & Africa: This region is the smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.
Key Players
  • Abbott (US)
  • MedMira Inc. (Canada)
  • Qaigen Inc. (US)
  • Thermo Fisher Scientific (US)
  • Cepheid (Danaher Corporation) (US)
  • Hoffmann-La Roche AG (Switzerland)
  • Diasorin S.p.A (Italy)
  • Bio-Rad Laboratories, Inc. (US)
  • bioMeriuex (France)
  • Becton Dickinson and Company (US)
  • Hologic, Inc. (US)
  • GenePOC Inc. (Canada)
  • Meridian Bioscience (US)
  • OraSure Technologies (USTop of FormBottom of Form
Posted by at No comments:
Subscribe to: Posts (Atom)